# An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

> **NCT01418677** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 19 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** E7389
- **DRUG:** E7389
- **DRUG:** E7389

## Key facts

- **NCT ID:** NCT01418677
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2014-07
- **Final completion:** 2015-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01418677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01418677, "An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01418677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*